Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

BioReference Laboratories, Inc. Announces Earnings Date for Third Quarter for Fiscal Year 2013



BioReference Laboratories, Inc. Announces Earnings Date for Third Quarter for
Fiscal Year 2013

ELMWOOD PARK, N.J., Aug. 22, 2013 (GLOBE NEWSWIRE) -- Bio-Reference
Laboratories, Inc. (Nasdaq:BRLI) announced today it plans to issue earnings
results for the third quarter of fiscal 2013 before the open of market trading
on Thursday, August 29, 2013. The Company's earnings conference call is to
take place the same day at 10:30 a.m. EDT. The call will be hosted by Marc D.
Grodman M.D., President and Chief Executive Officer.

The live Web cast will be available at the Company's corporate Web site,
www.bioreference.com and through www.streetevents.com. To listen to the live
call please go to the Web site ten minutes before the conference call is
scheduled to begin. You will need to register as well as download and install
any necessary audio software. The Web cast will be archived, on both Web
sites, for 30 days following the call.

About BioReference Laboratories, Inc.

BRLI is a clinical testing laboratory offering testing, information and
related services to physician offices, clinics, hospitals, employers and
governmental units. We believe that we are the fourth largest full-service
laboratory in the United States and the largest independent regional
laboratory in the Northeastern market. BRLI offers a comprehensive list of
laboratory testing services utilized by healthcare providers in the detection,
diagnosis, evaluation, monitoring and treatment of diseases. BRLI primarily
focuses on esoteric testing, molecular diagnostics, anatomical pathology,
women's health and correctional health care.

Statements included in this release that are not historical in nature, are
intended to be, and are hereby identified as "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995,
many of which are beyond our ability to control or predict. Forward-looking
statements may be identified by words such as "expects," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates," "will" or words of
similar meaning and include, but are not limited to, statements about the
expected future business and financial performance of Bio-Reference
Laboratories, Inc. and its subsidiaries. Statements looking forward in time
are included in this release pursuant to the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. Such statements involve
known and unknown risks and uncertainties that may cause the Company's actual
results in future periods to be materially different from any future
performance suggested herein. Risks and uncertainties that may affect the
future results of the company include, but are not limited to, adverse results
from future government investigations, lawsuits or private actions, including
the lawsuit described herein, the competitive environment, changes in
government regulations, changing relationships with customers, payers,
suppliers and strategic partners and other and other risks and uncertainties
detailed from time to time in our filings with the Securities and Exchange
Commission. We undertake no obligation to publicly update or review any
forward-looking information, whether as a result of new information, future
developments or otherwise.

                             www.bioreference.com

CONTACT: Tara Mackay
         Investor Relations Coordinator
         (201) 791-2600
         (201) 791-1941 (fax)
         tmackay@bioreference.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement